Advertisement

Topics

Palmetto, Anthem to cover use of Myriad's breast cancer recurrence test

06:56 EDT 18 Aug 2017 | SmartBrief

Myriad Genetics obtained positive coverage decisions from Anthem and Medicare contractor Palmetto GBA for its EndoPredict bre -More

Original Article: Palmetto, Anthem to cover use of Myriad's breast cancer recurrence test

NEXT ARTICLE

More From BioPortfolio on "Palmetto, Anthem to cover use of Myriad's breast cancer recurrence test"

Advertisement
Quick Search
Advertisement
Advertisement